Lupin receives FDA approval for Sevelamer Carbonate tabs

January 25, 2021 | Monday | News

Sevelamer Carbonate tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis

Source credit: Shutterstock

Lupin Limited, a global pharmaceutical company, announced that it has received approval for its Sevelamer Carbonate tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvela® tablets, 800 mg, of Genzyme Corporation.

Sevelamer Carbonate tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.

Sevelamer Carbonate tablets (RLD: Renvela®) had estimated annual sales of $348 million in thUS (IQVIA MAT September 2020).